Author supplied keywords
- *anticoagulant therapy
- *antithrombocytic agent/dt [Drug Therapy]
- *antithrombocytic agent/pe [Pharmacoeconomics]
- *coronary artery disease/dm [Disease Management]
- *coronary artery disease/su [Surgery]
- *drug eluting stent
- *in-stent restenosis/co [Complication]
- *in-stent restenosis/dm [Disease Management]
- *in-stent restenosis/dt [Drug Therapy]
- *in-stent restenosis/et [Etiology]
- *in-stent restenosis/pc [Prevention]
- acetylsalicylic acid/dt [Drug Therapy]
- artery intima proliferation
- clinical trial
- coronary stent
- cost effectiveness analysis
- death
- drug cost
- drug efficacy
- drug mechanism
- drug safety
- equipment design
- health care cost
- heart infarction/co [Complication]
- human
- implantation
- mortality
- nonhuman
- paclitaxel/ct [Clinical Trial]
- paclitaxel/dt [Drug Therapy]
- paclitaxel/pd [Pharmacology]
- patient compliance
- primary prevention
- rapamycin/ct [Clinical Trial]
- rapamycin/dt [Drug Therapy]
- rapamycin/pd [Pharmacology]
- review
- risk factor
- thrombogenesis
- thrombogenicity
- transluminal coronary angioplasty
- vascular patency
Cite
CITATION STYLE
APA
J., B.-M., B., I., & J.J., B. (2007). Dual antiplatelet therapy and drug eluting stents: A marriage of convenience. Thrombosis Journal. J.J. Badimon, Cardiovascular Biology Research Laboratory, Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, United States. E-mail: juan.badimon@mssm.edu: BioMed Central Ltd. Retrieved from http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=2007573513
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free